Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Syros Pharmaceuticals (SYRS)
Syros Pharmaceuticals (SYRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 152,946
  • Shares Outstanding, K 21,067
  • Annual Sales, $ 14,880 K
  • Annual Income, $ -94,650 K
  • 60-Month Beta 1.82
  • Price/Sales 23.04
  • Price/Cash Flow N/A
  • Price/Book 4.02
Trade SYRS with:

Options Overview Details

View History
  • Implied Volatility 144.08% ( +30.94%)
  • Historical Volatility 61.24%
  • IV Percentile 82%
  • IV Rank 46.42%
  • IV High 303.66% on 03/23/23
  • IV Low 5.84% on 11/14/23
  • Put/Call Vol Ratio 0.02
  • Today's Volume 130
  • Volume Avg (30-Day) 18
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 415
  • Open Int (30-Day) 423

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -1.23
  • Number of Estimates 3
  • High Estimate -1.07
  • Low Estimate -1.38
  • Prior Year -1.28
  • Growth Rate Est. (year over year) +3.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.36 +14.15%
on 01/25/24
7.88 -7.87%
on 02/06/24
+0.76 (+11.69%)
since 01/23/24
3-Month
2.47 +193.93%
on 12/04/23
8.17 -11.14%
on 01/02/24
+4.56 (+168.89%)
since 11/22/23
52-Week
2.09 +247.34%
on 10/19/23
8.17 -11.14%
on 01/02/24
+3.40 (+88.08%)
since 02/23/23

Most Recent Stories

More News
Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 24.11% and 0.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

SYRS : 7.26 (+2.40%)
ARAV : 0.0401 (-13.39%)
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Misses Revenue Estimates

Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of 11.11% and 13.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

TNGX : 11.50 (-0.09%)
SYRS : 7.26 (+2.40%)
ImmunityBio (IBRX) Stock Jumps 43.2%: Will It Continue to Soar?

ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase...

IBRX : 3.50 (-33.21%)
SYRS : 7.26 (+2.40%)
Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host...

SYRS : 7.26 (+2.40%)
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted...

SYRS : 7.26 (+2.40%)
Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Lags Revenue Estimates

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -0.79% and 123.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

SYRS : 7.26 (+2.40%)
VRDN : 18.77 (+4.34%)
Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for...

SYRS : 7.26 (+2.40%)
Syros to Participate in Upcoming Investor Conferences in March

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive...

SYRS : 7.26 (+2.40%)
Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host...

SYRS : 7.26 (+2.40%)
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted...

SYRS : 7.26 (+2.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients...

See More

Key Turning Points

3rd Resistance Point 8.33
2nd Resistance Point 7.99
1st Resistance Point 7.63
Last Price 7.26
1st Support Level 6.93
2nd Support Level 6.59
3rd Support Level 6.23

See More

52-Week High 8.17
Last Price 7.26
Fibonacci 61.8% 5.85
Fibonacci 50% 5.13
Fibonacci 38.2% 4.41
52-Week Low 2.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar